Pfizer (NYSE:PFE) Trading Up 2% - Time to Buy?

Key Points

• Pfizer shares rose 2% to $28.51 on increased trading volume after the company reported quarterly earnings and revenue above analyst expectations. Management maintained fiscal 2026 EPS guidance of $2.80–$3.00.
• Investors see potential in Pfizer’s oncology pipeline and roughly 6% dividend yield as possible supports for long-term growth and income, while institutional ownership remains high at 68.36%.
• The outlook remains mixed: Pfizer continues to underperform the S&P 500, its turnaround is viewed as gradual, and analysts maintain a consensus “Hold” rating with an average price target of $28.28.

Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price was up 2% on Monday . The stock traded as high as $28.70 and last traded at $28.51. Approximately 44,692,075 shares traded hands during mid-day trading, an increase of 7% from the average session volume of 41,789,922 shares. The stock had previously closed at $27.96.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Oncology pipeline supports long-term growth: Pfizer’s oncology strategy is centered on Padcev, supported by potential label expansions and pipeline candidates such as PF-08634404. Investors may view this portfolio as important for offsetting revenue pressure from older products and strengthening growth beyond COVID-related products. From Padcev to PF-08634404: Pfizer's Oncology Growth Push
• Positive Sentiment: Dividend appeal is supporting demand: Pfizer is being highlighted as a high-yielding defensive stock as investors seek income and become more cautious about elevated technology and artificial-intelligence valuations. Its dividend may help support the shares while the company executes its growth plan. 3 Stocks for Investors Who Still Believe Cash Is King
• Positive Sentiment: Higher earnings expectations: Erste Group Bank increased its fiscal 2026 EPS estimate for Pfizer, adding to the constructive analyst outlook. Pfizer’s latest quarterly results also exceeded consensus estimates for earnings and revenue, while management’s full-year EPS guidance remains $2.80–$3.00. Pfizer FY2026 EPS Estimate Increased by Erste Group Bank
• Neutral Sentiment: Recovery remains a work in progress: Pfizer has raised its outlook, but analysts characterize its turnaround as less visible than some other companies’ recoveries. This reinforces the potential for gradual improvement rather than an immediate acceleration in results. Pfizer and Starbucks: One Turnaround Is Built to Last, and One Isn't
• Negative Sentiment: Relative performance remains a concern: Pfizer has underperformed the S&P 500 over the past year, highlighting ongoing investor concerns about growth, execution, and the company’s post-pandemic revenue transition. Analysts remain moderately optimistic, but the underperformance could limit enthusiasm for the stock. Is Pfizer Stock Underperforming the S&P 500?

Analyst Upgrades and Downgrades

Several research firms have weighed in on PFE. Royal Bank Of Canada upgraded Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective on the stock in a research report on Tuesday, June 9th. Guggenheim lowered their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research report on Friday, August 7th. Wolfe Research reiterated an "underperform" rating and issued a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. BMO Capital Markets dropped their price objective on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, July 13th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Pfizer has a consensus rating of "Hold" and an average price target of $28.28.

Pfizer Stock Performance

The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company has a market cap of $162.50 billion, a P/E ratio of 37.51 and a beta of 0.34. The stock's fifty day moving average price is $25.55 and its two-hundred day moving average price is $26.30.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the firm posted $0.78 earnings per share. The firm's quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.0%. Pfizer's dividend payout ratio is 226.32%.

Institutional Investors Weigh In On Pfizer

Institutional investors have recently added to or reduced their stakes in the business. Godfrey Financial Associates Inc. bought a new position in Pfizer during the 4th quarter worth $26,000. Keb Asset Management LLC bought a new position in shares of Pfizer during the second quarter worth about $26,000. Field & Main Bank acquired a new position in shares of Pfizer in the second quarter worth approximately $27,000. HFM Investment Advisors LLC boosted its holdings in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. Finally, Evolution Wealth Management Inc. increased its position in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 566 shares during the period. 68.36% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source